Cargando…
Safety and efficacy of azacitidine in myelodysplastic syndromes
PURPOSE: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. SUMMARY: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression t...
Autores principales: | Vigil, Carlos E, Martin-Santos, Taida, Garcia-Manero, Guillermo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948932/ https://www.ncbi.nlm.nih.gov/pubmed/20957213 |
Ejemplares similares
-
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
por: Ritchie, Ellen K
Publicado: (2012) -
PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023) -
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
por: Garcia-Manero, G, et al.
Publicado: (2016) -
The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009) -
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)